One swollen, painful leg or sudden breathlessness needs emergency care. Call 911.
The rest of this guide covers what a positive report actually says, why one copy and two copies behave differently, who is usually offered the test, and what the result changes in ordinary life.
Factor V Leiden is a single inherited letter change in the F5 gene, the gene that carries the instructions for clotting factor V. The variant is usually written as F5 c.1691G>A, or at the protein level as p.Arg506Gln, often shortened to R506Q. It is the most common inherited thrombophilia, meaning the most common inherited tendency toward venous clotting 1.
You will see the same thing written several ways. Factor 5 Leiden, factor five Leiden, factor V mutation Leiden, Leiden factor V and simply V Leiden all refer to one variant in one gene. There is only one Factor V Leiden variant, so a laboratory is either looking for it or it is not.
Two things make it unusual compared with most of what appears on a blood panel. First, it is a genotype rather than a measurement, so the result is a category and not a number that drifts with sleep, training or illness. Second, it is fixed from conception. A person is born with zero, one or two copies, and that never changes. You do not develop it, you do not grow out of it, and there is no value to bring back into range.
What it describes is a tendency, not an event. The variant slightly tilts the balance between clot formation and clot shutdown in the direction of forming clots. Whether that tilt ever turns into an actual clot depends on everything else happening in a person's body and life, which is why so many carriers live their whole lives without knowing.
Calling it a factor V Leiden deficiency is a common mix-up, because nothing is deficient. People with the variant make a normal amount of factor V protein, and that protein works perfectly well at starting a clot. The difference is in how easily the protein can be switched off again.
The confusion comes from the company it keeps. Several other inherited clotting tendencies genuinely are deficiencies, where the body produces too little of a natural brake on clotting, for example protein C, protein S or antithrombin. Those are measured as levels in the blood, and a low level is the finding. Factor V Leiden sits in the same conversation, so the word deficiency gets borrowed, incorrectly.
There is also a genuinely different condition called factor V deficiency, a rare bleeding disorder in which too little factor V is made. It is almost the opposite situation. Factor V Leiden tilts toward clotting, factor V deficiency tilts toward bleeding, and the similar names cause real confusion on lab paperwork. If a report mentions factor V in any form, it is worth confirming with the ordering clinician which of the two was actually tested.
The variant removes one of the sites where the body normally cuts factor V to switch it off. Clotting runs as a cascade, with each step amplifying the next. Factor V is activated into factor Va, which acts as a powerful accelerator for generating thrombin, the enzyme that converts fibrinogen into the fibrin mesh of a clot.
The body controls that acceleration with activated protein C, a natural brake that cuts factor Va at specific positions and takes it out of service. In Factor V Leiden, the amino acid at one of those cutting positions is swapped, so that particular cut cannot be made cleanly. Factor Va therefore stays active for longer than it should, and thrombin generation continues further than it would otherwise. Laboratories call this activated protein C resistance, and it is the measurable consequence of the variant 1.
It is worth being precise about the size of this effect. The brake is not removed, it is slowed. Other cutting sites still work, and all the other natural anticlotting systems still function. That is why the practical result is a modest shift in balance rather than a switch flipped from off to on, and why the variant tends to matter most when it is combined with something else that also pushes toward clotting, such as prolonged immobility, injury or recovery from surgery.
It also explains why the effect shows up mainly in veins rather than arteries. Thrombin-driven, fibrin-rich clots are the characteristic clots of slow-flowing venous blood, while arterial events are driven more by plaque and platelet behaviour. Research suggests that the clearest and most consistent association for this variant is with venous clotting rather than arterial disease 1.
One copy, called heterozygous, is by far the more common finding and carries a modest increase in risk, while two copies, called homozygous, is much rarer and carries a considerably larger increase. Everyone inherits one F5 gene from each parent, so three results are possible: no copies of the variant, one copy, or two.
A heterozygous result means one gene carries the variant and one does not. Roughly half of a person's factor V behaves normally under activated protein C, and half resists. Carrying one copy is associated with an increased lifetime risk of venous thromboembolism rather than any certainty of it, and most heterozygous carriers never experience a clot 2.
Factor V Leiden homozygous means both genes carry the variant. Essentially all of the person's factor V resists being switched off, activated protein C resistance in the laboratory is more pronounced, and the increase in venous clot risk is substantially greater than with one copy 2. This result is uncommon, and it is the version most likely to prompt a referral to a specialist in blood disorders.
There is also a combined situation worth knowing about. A person can carry one copy of Factor V Leiden alongside a different inherited clotting variant, and risk factors of this kind tend to stack rather than simply sit side by side 2. This is one reason a clinician reviews the whole picture, including personal and family clotting history, rather than reacting to a single line on a genetic report.
| Result on the report | What it means genetically | General risk picture |
|---|---|---|
| Not detected | Neither F5 gene carries the variant | No added risk from this particular variant |
| Heterozygous | One of the two F5 genes carries it | Modest increase in venous clot risk, most carriers never clot |
| Homozygous | Both F5 genes carry it | Larger increase in venous clot risk, uncommon result |
Because the variant has incomplete penetrance, meaning carrying it does not reliably produce the outcome. The majority of people who inherit Factor V Leiden go through life without a venous clot, and many are only identified because a relative was tested 2.
The useful way to think about it is as one contributor on a list rather than a cause on its own. Venous clots usually happen when several conditions line up at once: slowed blood flow, some injury or irritation to a vein wall, and blood that clots more readily than usual. The variant only affects the third item, and only partially. Without the first two, it often has nothing to act on.
That also explains the pattern seen in carriers who do clot. Events tend to cluster around identifiable triggers, such as recovery from surgery, a significant injury, a long stretch of immobility, or a serious illness that keeps someone in bed. Age matters too, because background clotting risk rises steadily over the decades regardless of genotype.
The practical consequence is that a positive result is better understood as information for specific moments than as a daily burden. For most carriers, the result changes what their surgical team is told and what symptoms they treat as urgent, and very little else. A clinician who knows the person's full history is the right one to say where their individual risk sits.
The link is with venous clots, most characteristically deep vein thrombosis in the leg. Deep vein thrombosis typically shows up as swelling, pain, warmth or discolouration in one leg rather than both, and it is the event carriers are most often counselled about.
There is a well described and slightly counterintuitive pattern here. The variant is associated more strongly with deep vein thrombosis alone than with pulmonary embolism, which is the condition that arises when part of a clot travels to the lungs, a pattern sometimes called the factor V Leiden paradox 3. This does not mean a carrier cannot have a pulmonary embolism. It means the variant is found relatively more often among people presenting with leg clots than among people presenting with lung clots.
Clots in less common sites, such as the veins of the abdomen or the brain, are also discussed in connection with inherited clotting tendencies, and their appearance without a clear trigger is one of the reasons a clinician may consider testing 2.
Whatever the genotype, the symptoms that need immediate assessment are the same for everyone. One swollen, painful leg, sudden shortness of breath, chest pain that worsens with breathing, or coughing up blood all need emergency care straight away. Carriers do not need to wait for a worse symptom because they already know their result, and non-carriers are not protected by a negative one.
Testing is typically considered when there is a specific reason to ask the question, not as a routine screen for the general population 2. The situations that most often prompt it include a venous clot at a relatively young age, a clot with no clear trigger, clots that keep recurring, a clot in an unusual site, or a close relative with a confirmed inherited clotting variant.
The reasoning behind the selectivity is straightforward. A result only earns its place if it could change something, such as how a clotting episode is understood, how closely someone is watched around a high-risk period, or whether relatives are offered counselling. Testing everyone would identify a large number of people who will never clot, while offering them little they can act on.
Family testing is its own conversation. When one person is confirmed as a carrier, first-degree relatives may be offered testing, usually with counselling first so that everyone understands what a positive or negative answer will and will not tell them 2. Testing children is generally approached cautiously, since clotting events in childhood are rare and the information rarely changes anything before adulthood.
Many people now encounter the variant through consumer genetic reports rather than a clinic. A result from that route is worth taking to a clinician, both to confirm it through a clinical laboratory and to put it in the context of personal and family history, which is what gives the genotype meaning.
There are two laboratory routes, and they answer slightly different questions. The first is a clot-based activated protein C resistance assay, which measures how the blood behaves when activated protein C is added. The second is a DNA test that looks directly for the F5 variant. A common sequence is to screen with the functional assay and confirm a positive or ambiguous result with genetic testing 4.
Each has its strengths. The functional assay reflects what the blood actually does, so it can also pick up resistance arising from causes other than this variant. Its results, however, can be influenced by other conditions affecting coagulation and by sample handling, which is one reason modified versions of the assay were developed 4. The genetic test gives a clean categorical answer, not detected, heterozygous or homozygous, and that answer is unaffected by an acute clot, by illness or by medication.
Practically, it is a standard blood draw. No fasting is required, no special preparation is needed, and because the genotype never changes, it is a once-in-a-lifetime test. Repeating it later adds nothing. What changes over time is the context around it: age, surgeries, pregnancies, injuries and other health conditions.
Timing is worth a word. A clinician may decide when, and whether, to test around an acute clotting episode, because results can be interpreted differently in that window and the immediate management of a clot is decided on clinical grounds in any case. Treatment decisions belong to a licensed provider.
Fibrinogen Activity measures the protein that forms the final fibrin mesh of a clot, so it describes clotting capacity in the moment, while the F5 genotype describes an inherited tendency that stays the same for life. The two answer different questions, and reading them together is more informative than reading either alone. Fibrinogen also rises as part of the body's general inflammatory response, so a single value reflects what is happening the week of the draw. The full explanation of Fibrinogen Activity, how it is measured, what typical and optimal ranges look like and what a high or low result may reflect, lives on its own marker page.
The genotype is one line in a wider clotting picture, and the markers around it describe how blood is behaving now. A clinician decides which of these are relevant to any individual, but the common companions are listed below.
| Marker | Typical lab reference range | FitScript optimal range | What it adds next to a genotype result |
|---|---|---|---|
| Factor V Leiden (F5 genotype) | Reported as not detected, heterozygous or homozygous, not as a number | Not applicable, this is a genotype | Inherited tendency, fixed for life |
| Fibrinogen Activity | 200 to 400 mg/dL | 200 to 300 mg/dL | The protein that forms the clot mesh, also an inflammation marker |
| Platelet count | Commonly around 150,000 to 450,000 per microlitre | Not listed here | The cells that form the initial plug |
| Prothrombin time with INR | Lab specific, printed with each result | Not listed here | Speed of one arm of the clotting cascade |
Reference ranges are typical lab reference ranges and they vary by laboratory, age and sex, so the range printed on your own report is the one that applies to you. FitScript's optimal range for Fibrinogen Activity is an optimization target, not a diagnostic cut-off.
A count of platelets describes the cells that start a clot, and a very high or very low count is interpreted in its own right rather than as a comment on the genotype. The prothrombin time and INR describe how quickly one clotting pathway completes, which is a different measurement again. FitScript's membership covers 150+ biomarkers tested per year, interpreted by Atlas, FitScript's AI health advisor, which is the kind of setting where related markers are read as a group rather than one line at a time.
These are the situations where carrier status is most likely to be discussed, because they combine reduced movement, tissue injury and a temporary shift toward clotting. Studies indicate that surgical and trauma patients are a group in which venous thromboembolism among Factor V Leiden carriers deserves specific attention 5.
That does not mean the genotype is the deciding factor. Evidence suggests that the procedure itself and a person's other risk factors weigh heavily in how adults carrying the variant fare through noncardiac surgery, rather than carrier status being read in isolation 6. Surgical and anaesthetic teams already assess clot risk for every patient, and a known variant is added to that assessment rather than replacing it.
The practical step for a carrier is simple and non-medical: make sure the result is on record and mention it during pre-operative assessment, before the day of the procedure if possible. The same applies after a significant injury, during a hospital stay, or through any extended period of reduced mobility. What, if anything, is done about it is a clinical decision, and treatment decisions belong to a licensed provider.
Hormonal and reproductive circumstances come up in the same conversation. Estrogen-containing contraception and pregnancy are both associated with a higher clotting tendency, and in people carrying the variant a licensed provider weighs those circumstances together with personal and family history 2.
A negative result means this one variant was not found, and nothing more. It does not mean a person cannot form a clot, and it does not clear every inherited or acquired clotting tendency.
Several other inherited conditions push in the same direction, including deficiencies of natural brakes such as protein C, protein S and antithrombin, and a different variant affecting prothrombin. Acquired causes matter at least as much and often more, including immobility, major surgery, significant injury, active cancer, some autoimmune conditions, obesity and age. Testing panels are chosen by a clinician based on the clinical question being asked.
There is also a narrower point about the functional assay. Activated protein C resistance can be present for reasons other than Factor V Leiden, which is why a resistant result and a genetic result are not interchangeable and why confirmatory genetic testing is used 4.
The behaviour that follows a negative result should therefore be identical to the behaviour that follows a positive one when symptoms appear. Sudden one-sided leg swelling and pain, or sudden breathlessness, are emergencies regardless of what a genetic report says.
It means close relatives have a meaningful chance of carrying the same variant, because this is inherited in a straightforward autosomal pattern. A parent with one copy passes that copy to each child with a one in two chance, independently for each child. Siblings of a carrier also have a substantial chance of carrying it.
This is why a positive result is often described as family information rather than purely personal information. Relatives may choose to be tested, usually after a conversation that covers what the result can and cannot tell them, and that discussion is part of standard practice around inherited clotting variants 2.
Not everyone wants to know, and that is a legitimate choice. A negative result in a relative removes one question, while a positive result in a relative who has never clotted usually changes very little day to day. The value is concentrated in specific moments, such as planning a major operation or a pregnancy, when a clinician benefits from having the information in advance.
It is also worth recording the result somewhere findable, because the people most likely to need it are the ones meeting you for the first time, in a pre-operative clinic or an emergency department.
Immediately, if clot symptoms appear, and in a planned way around any high-risk period or decision. Those two categories cover most of what matters.
Emergency signs come first. One swollen, painful, warm or discoloured leg, sudden shortness of breath, chest pain that sharpens with a deep breath, coughing up blood, or sudden severe headache with new neurological symptoms all warrant emergency care rather than a next-available appointment. Call 911 for these.
The planned conversations are different in tone. They include booking any surgery or procedure, planning a pregnancy or discussing contraception, a new diagnosis that affects mobility, a family member's positive result, or simply receiving a genetic report you did not fully expect. In each of these, the useful move is to bring the actual report and the family history to a clinician who can interpret them together. Bring any result that sits outside the standard range or looks suboptimal to the same conversation rather than acting on it alone, and never set aside an abnormal result on the assumption that it is explained by a known variant.
This guide is educational and is not medical advice. Discuss your own results, and any decision about next steps or treatment, with a clinician or licensed provider who knows your history.
No. It is an inherited variant in one gene, not an illness, and on its own it causes no symptoms. It describes a tendency for blood to clot slightly more readily, which may or may not ever produce a clot. A clinician interprets what it means for you alongside your personal and family history.
No. Most carriers never experience a venous clot. The variant usually matters most when it combines with other circumstances, such as major surgery, a significant injury or a long period of immobility. Knowing your result mainly helps clinicians plan around those specific moments.
Heterozygous means one of your two copies of the F5 gene carries the variant, which is the far more common result and raises venous clot risk modestly. Homozygous means both copies carry it, which is uncommon and raises risk more. A clinician, often a blood specialist, reviews what a homozygous result means for you.
It is a standard blood draw with no fasting and no special preparation. A laboratory can look at how your blood responds to activated protein C, test your DNA directly for the variant, or do both. Your report will say not detected, heterozygous or homozygous.
No. You are born with zero, one or two copies of the variant and that never changes, so this is a once-in-a-lifetime test. What changes is the context around it, such as your age, surgeries, pregnancies and other health conditions. Repeating the genetic test adds nothing new.
That is a decision to make with a clinician, usually after a conversation about what a positive or negative answer would actually change. A parent with one copy passes it to each child with a one in two chance, so close relatives often have the option. Testing children is generally approached cautiously, because the information rarely changes anything before adulthood.
No, and the names are easy to confuse. Factor V Leiden tilts the balance toward clotting, while factor V deficiency is a rare bleeding disorder in which too little factor V is made. If a report mentions factor V, confirm with the ordering clinician which test was actually run.
One swollen, painful, warm or discoloured leg, sudden shortness of breath, chest pain that worsens with a deep breath, or coughing up blood all need emergency care. Call 911 rather than waiting for an appointment. This applies to everyone, whether or not a genetic test has been done.